The Next Generation of Covid Vaccines: Novavax’s Protein-Based Shot

Novavax recently received authorization from the Food and Drug Administration for their updated protein-based Covid vaccine, targeting the highly contagious omicron subvariant JN.1. This approval opens the door for Novavax to compete with Pfizer and Moderna’s mRNA vaccines in the upcoming fall and winter seasons.

Unlike Pfizer and Moderna, Novavax’s vaccine is protein-based, which means it cannot be as quickly updated to target new strains of the virus. However, the company claims that their shot still offers protection against descendants of JN.1 currently dominant in the U.S., such as KP.2.3, KP.3, KP.3.1.1, and LB.1. Novavax CEO John Jacobs emphasized the cross-reactivity of their vaccine against JN.1 lineage viruses.

Novavax anticipates that their vaccine will be widely available at thousands of locations throughout the U.S., including retail pharmacies, independent pharmacies, and regional grocers. This widespread distribution is expected to make the Novavax shot accessible to a large portion of the population.

The FDA’s approval of Novavax’s vaccine comes shortly after authorizing updated mRNA shots from Pfizer and Moderna, which target a different offshoot of JN.1 known as KP.2. This competitive landscape highlights the diversity of options available to individuals seeking Covid vaccination.

Public health officials view Novavax’s protein-based vaccine as a valuable alternative for individuals hesitant to receive mRNA shots from Pfizer and Moderna. While Pfizer and Moderna use newer technology to stimulate an immune response, Novavax relies on established protein-based technology used in routine vaccinations against other diseases.

The demand for new Covid shots this fall and winter remains uncertain, with only around 22.5% of the U.S. population fully vaccinated. Novavax’s entry into the market provides a new choice for individuals looking to protect themselves against Covid and its variants.

By introducing Novavax’s protein-based vaccine into the Covid vaccination landscape, individuals now have a broader range of options to choose from when considering their health and safety in the ongoing pandemic. The diverse approaches taken by different vaccine manufacturers reflect the innovative spirit driving our collective efforts to combat Covid and protect public health.